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ABBREVIATIONS 
 
 JP: Japanese Pharmacopoeia 
 
 ETO : Etoricoxib 
 
 SER : Serratiopeptidase 
 
 CNS: Central Nervous System 
 
 NSAIDs: Non-Steroidal Anti Inflammatory Drugs 
 
 COX: Cyclo-oxygenase 
 
 c-GMP: cyclic Guanosine monophosphate 
 
 DMSO: Di-Methyl Sulfoxide 
 
 FDA : Food and Drug Administration 
 
 ICH : International Conference of Harmonization 
 
 USP : United States Pharmacopoeia 
 
 API: Active Pharmaceutical Ingredient 
 
 UV: Ultraviolet 
 
 RP-HPLC: Reverse Phase High Performance Liquid Chromatography 
 
 HPTLC: High Performance Thin Layer Chromatography 
 
 NMR: Nuclear Magnetic Resonance 
 
 LC-MS: Liquid Chromatography-Mass Spectroscopy 
 
 GC-MS: Gas Chromatography-Mass Spectroscopy 
 
 ESI: Electro Spray Ionization 
 
 TOF: Time of Flight 
 
 LC-MS-MS: Liquid Chromatography-Tandem Mass Spectroscopy 
 
 UPLC: Ultra Performance Liquid Chromatography 
 
 ACN: Acetonitrile 
 
 OPA: Ortho Phosphoric acid 
 
 S.D.: Standard Deviation 
 
 RSD: Relative Standard Deviation 
 
 CV: Coefficient of Variance 
 
 S/N: Signal to Noise Ratio 
  
 
 
 
 
 
 Rf: Retardation Factor 
 
 i.d.: Internal Diameter 
 
 µg: Microgram 
 
 mg : Milligram 
 
 ml: Milliliter 
 
 µl: Microliter 
 
 mm: Millimeter 
 
 cm: Centimeter 
 
 ng: Nanogram 
 
 MCC : Microcrystalline Cellulose 
 
 Min.: Minutes 
 
 AUC: Area Under Curve 
 
 %: Percentage 
 
 AR: Analytical Grade Reagent 
 
 °C: Degree Centigrade 
 
 M: Molar 
 
 r2: Correlation Coefficient 
 
 Rt : Retention Time 
 
 v/v : Volume/Volume 
 
 Std.: Standard 
 
 LOD: Limit of Detection 
 
 LOQ: Limit of Quantification 
 
 PDA: Photo Diode Array 
 
 ANOVA: Analysis of Variance 
 
 C.F.: Correction Factor 
 
 d.f.: Degree of Freedom 
 
 C.S.S.: Column Sum of Squares 
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INTRODUCTION 
 
 
 
  
 
 
 
1. INTRODUCTION 
 
 
1.1 INTRODUCTION OF MUSCLE SPASM1-3: 
 
Muscle spasm: A muscle spasm, or muscle cramp, is an involuntary 
contraction of amuscle. Muscle spasms occur suddenly, usually resolve 
quickly, and are often painful. Muscles are complex structures that cause 
movement in the body. There are three types of muscle in the body: 
 
 Heart muscle pumps blood (cardiac muscle). 
 
 Skeletal muscle moves the external body parts, like the arms and 
legs, and the neck. 
 Smooth muscle moves portions of hollow structures inside the body. 
Examples include the muscles that line the stomach and intestine, 
muscles that line large arteries and the muscles of the uterus. 
Causes: 
 
There are a variety of causes of muscle spasms. 
 
 Muscle is overused and tired, particularly if it is overstretched 
 
 Unfamiliar exercise activities 
 
 Atherosclerosis 
 
 Systemic illnesses like diabetes, anemia and kidney and thyroid disease 
 
Symptoms and signs: 
 
The symptoms of muscle spasm depend upon the muscle involved and 
the circumstances leading up to the spasm. Skeletal muscle spasm usually 
involves muscles that are being asked to do excessive work. There is acute 
onset of pain as the muscle contracts. Most often, the spasm resolves 
spontaneously after a few seconds though it may last many minutes or longer. 
Usually, the patient will feel the need to stretch the muscle involved, thus 
relieving the spasm and resolving the episode. Smooth muscle spasm will cause 
colicky pain that comes and goes. The symptoms will depend upon the organ 
involved. 
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Treatment of muscle spasm: 
 
The treatment of smooth muscle spasm also depends upon the 
underlying cause. Various drugs used for muscle spasms are shown in table 1.1, 
 
Table 1.1: Classification of drugs 
 
 
 
 
 
 
 
Peripherally 
acting Muscle 
relaxants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Centrally acting 
Muscle relaxants 
 
Directly acting 
 
Muscle relaxants 
 
 
 
 
Non-depolarizing 
 
agent 
 
 
Depolarizing agent 
 
 
Ach release 
inhibitors 
 
Carbamic esters 
 
Benzodiazepines 
 
Anticholinergics 
 
Piperidine 
derivatives 
Others 
 
 
Curare alkaloids 
Tubocurarine, 
Dimethyltubocurarine  
  
4-Ammonium Atracurium, 
agents Cisatracurium,Gallamine 
  
Choline 
Succinylcholine, 
derivatives  
  
 
Botalinum toxin 
 
 
Meprobamate, Methocarbamol, Tybamate 
 
Diazepam, Lorazepam, Nitrazepam 
 
Orphenadrine 
 
Tolperisone,Etoricoxib 
 
Quinine, Baclofen, Thiocolchicoside 
 
Dantrolene 
 
Analgesic drugs 
 
Diclofenac, Ibuprofen, 
Serratiopeptidase 
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1.2 DRUG PROFILE OF ETORICOXIB4-5: 
 
Table 1.2: Drug Profile of ETORICOXIB 
 
 
Generic name Etoricoxib 
Description Etoricoxib is a white to off-white powder 
Chemical structure 
 
Chemical name 5-chloro-6'-methyl-3-[4- (methylsulfonyl)phenyl]-2,3'-
bipyridine 
Formula C18H15ClN2O2S 
Molecular mass 358.84. 
Category Analgesic 
Solubility Very soluble in acetic acid, methanol, freely soluble in 
water and in ethanol, soluble in acetic anhydride, 
slightly soluble in acetone, and practically insoluble in 
diethyl ether 
Mechanism of action This NSAID is a selective COX2 inhibitor (blocking the 
action of a substance in the body called cyclo-
oxygenase. Cyclo-oxygenase is involved in producing 
prostaglandins, in response to injury or certain 
diseases. These prostaglandins cause pain, swelling 
and inflammation). This inhibition results the analgesics 
and anti-inflammatory action peripherally 
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1.3 DRUG PROFILE OF SERRATIOPEPTIDASE6-7: 
 
Table 1.3: Drug Profile of Serratiopeptidase 
 
Generic Name Serratiopeptidase 
Description Off-white to light brown coloured powder, having characteristics 
odour 
Molecular mass  45,000 – 60,000 Da 
Category Anti-inflammatory 
Mechanism of 
action 
The mechanism of action of Serratiopeptidase appears to 
be hydrolysis of histamine, bradykinin and serotonin. 
Serratiopeptidase also has a proteolytic and fibrinolytic effect. This 
is achieved by dissolving the complement (specific proteins 
responsible for inflammation) and increasing the plasmin activity 
by inhibiting the plasmin inactivators. 
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1.4 INTRODUCTION TO VALIDATION OF ANALYTICAL METHODS 
(USP/ICH) 8 
 
Method validation, according to the United States Pharmacopoeia (USP), 
is performed to ensure that an analytical methodology is accurate, specific, 
reproducible, and rugged over the specified range that an analyte will be 
analyzed. Regulated laboratories must perform method validation in order to be 
in compliance with FDA regulations. In a 1987 guideline (Guideline for submitting 
samples and analytical data for methods validation), the FDA designated the 
specifications in the current edition of the USP as those legally recognized when 
determining compliance with t he Federal Food, Drug and Cosmetic Act. It can 
be referred to as the “eight steps of method validation,” as shown in Figure 1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Eight steps of method validation 
 
ICH has suggested the guideline for validation of analytical procedure under the 
heading “Validation of Analytical Procedures: Methodology” in the section Q2B. 
ICH divided the validation characteristics somewhat differently, as outlined in 
Figure 1.2. 
 
 
 
 
 
 
 
 
 
 
      5 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: ICH method validation parameters 
  
The differences between the USP and ICH terminology is, for the most part, one 
of semantics—with one notable exception. ICH treats system suitability as a part 
of method validation, whereas the U SP treats it in a separate chapter. 
1.4.1 Accuracy 
 
Accuracy is the measure of exactness of an analytical method, or the closeness 
of agreement between the measured value and the value that is accepted either 
as a conventional, true value or an accepted reference value. Accuracy is 
measured as the percentage of analyte recovered by assay, by spiking samples 
in a blind study. 
 
1.4.2 Precision 
 
Precision is the measure of the degree of repeatability of an analytical method 
under normal operation and is normally expressed as the %RSD for a statistically 
significant number of samples. 
 
According to the ICH, precision should be performed at three different levels: 
repeatability, intermediate precision, and reproducibility. 
(a) Repeatability refers to the results of the method operating over a short time  
interval under the same conditions (inter-assay precision). It should be 
determinedfromaminimum of nine determinations covering the specified                               
6 
 
   
(b)  range of the procedure or from a minimum of six determinations at 100% of 
the test or target concentration. 
(b) Intermediate precision refers to the results from within-lab variations due to 
random events such as differences in experimental periods, analysts, 
equipment, and so forth. In determining intermediate precision, experimental 
design should be analyzed so that the effects of the individual variables can 
be monitored. 
(c) Reproducibility refers to the results of collaborative studies among 
laboratories. 
 
(d) Recommended data: Precision studies should include the S.D., R.S.D., C.V. 
and confidence interval. 
 
1.4.3 Specificity 
 
Specificity is the ability to measure accurately and specifically the analyte of 
interest in the presence of other components that may be expected to be present 
in the sample matrix. 
 
1.4.4 Limit of detection 
 
The limit of detection (LOD) is defined as the lowest concentration of an analyte 
in a sample that can be detected, though not necessarily quantitated. Several 
approaches for the determining the detection of limit is possible, depending upon 
weather the procedure is an instrumental or non-instrumental. 
 
1.4.5 Limit of quantification 
 
The limit of quantification (LOQ) is defined as the lowest concentration of an 
analyte in a sample that can be determined with acceptable precision and 
accuracy under the stated operational conditions of the method. Several 
approaches for the determining the quantification limit is possible, depending 
upon weather the procedure is an instrumental or non-instrumental. 
 
1.4.6 Linearity 
 
The linearity is the ability of analytical procedure to produce test results which are 
proportional to the concentration of analyte in samples within a given 
concentration range, either directly or by means of a well-defined mathematical 
transformation. Linearity should be determined by using a minimum of six 
standards whose concentration span 80–120% of the expected concentration 
range. 
7 
   
1.4.7 Range 
 
Range is the interval between the upper and lower levels of analyte that have 
been demonstrated to be determined with precision, accuracy, and linearity using 
the method. The range is normally expressed in the same units as the test 
results obtained by the method. 
1.4.8 Ruggedness 
Ruggedness, according to the USP, is the degree of reproducibility of the results 
obtained under variety of conditions, expressed as % RSD. These conditions 
include differences in laboratories, analysts, instruments, reagents, and 
experimental periods. 
 
1.4.9 Robustness 
 
Robustness is the capacity of a method to remain unaffected by small deliberate 
variations in method parameters. The robustness of a method is evaluated by 
varying method parameters such as percent organic solvent, pH, ionic strength, 
or temperature, and determining the effect on the results of the method. As 
documented in the ICH guidelines, robustness should be considered early in the 
development of a method. 
 
1.4.10 System suitability 
 
According to the USP, system suitability tests are an integral part of 
chromatographic methods. These tests are used to verify that the resolution and 
reproducibility of the system are adequate for the analysis to be performed. 
System suitability tests are based on the concept that the equipment, electronics, 
analytical operations, and samples constitute an integral system that can be 
evaluated as a whole. System suitability is the checking of a system to ensure 
system performance before or during the analysis of unknowns. Parameters such 
as plate count, tailing factors, resolution and reproducibility (% RSD retention 
time and area for repetitive injections) are determined and compared against the 
specifications set for the method.
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Table 1.4: System suitability parameters and 
recommendations 
 
Parameters 
 
Capacity factor (k’) 
 
Repeatability 
 
Relative retention 
 
 
Resolution (Rs) 
 
 
Tailing factor (T) 
 
Theoretical plates (N) 
 
Recommendation 
 
The peak should be well-resolved from other peaks and the 
void volume, generally k’>2.0 
 
RSD </= 1% for N >/= 5 is desirable. 
 
Not essential as long as the resolution is stated. 
 
Rs of > 2 between the peak of interest and the closest 
eluting potential interferences (impurity, excipients, 
degradation product, internal standard, etc. 
 
T of </= 2 
 
In general should be > 2000 
 
 
1.5. INTRODUCTION TO SPECTROPHOTOMETRIC METHODS 9 
 
Various spectrophotometric methods are available for the analysis of drugs in 
combined dosage forms, like 
 
 Simultaneous equations method 
 
 First order derivative method 
 
 Area under curve method 
 
1.5.1. Simultaneous equations method 
 
If a sample contains two absorbing drugs (X and Y) each of which absorbs at the 
Ȝmax of the other (as shown in figure Ȝ1and Ȝ2), it may be possible to determine 
both drugs by the technique of simultaneous equation. In this method, the 
absorbances of the solutions are measured at the Ȝ max of both the drugs. The 
criteria are that the ratios [(A2/A1) / (ax2/ax1)] and [(ay2/ay1) / (A2/A1)] should lie 
outside the range 0.1-2.0. 
 
Concentration of both drugs is calculated by solving the simultaneous 
equations 1 & 2.  
Cx = (A2 aY1 – A1 aY2) / (aY1 aX2 - aY2 aX1) ----- (1) 
                   Cy = (A1 aX2 - A2 aX1) / (aY1 aX2 - aY2 aX1) ------ (2) 
 
 
     9 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Overlain U.V. absorption spectra of two drugs 
 
Where, A1, A2= Absorbances of mixture at Ȝ1 & Ȝ2 
respectively, ax1 =Absorpitivity of first drug at Ȝ1, 
ax2 = Absorpitivity of first drug at Ȝ2, 
ay1=Absorpitivit y of second drug at 
Ȝ1, ay2 = Absorpitivity of second 
drug at Ȝ2. 
 
1.5.2 Derivative Spectrophotometric Method: 
 
For the purpose of spectral analysis in order to relate chemical structure to 
electronic transitions, and for analytical situations in which mixture contribute 
interfering absorption, a method of manipulating the spectral data is called 
derivative spectroscopy. 
 
Derivative spectrophotometry involves conversion of a normal spectrum to its 
first, second and higher derivative spectrum. In the context of derivative 
spectrophotometry, the normal absorption spectrum is referred to as the 
fundamental, zero order, or D0 spectrum. 
 
The first derivative spectrum is a plot of the rate of change of absorbance with 
wavelength against wavelength i.e. a plot of the slope of the fundamental 
spectrum against wavelength or a plot. The maximum positive and maximum 
negative slope respectively in the D spectrum correspond with a maximu m and 
minimum 
 
 10
 
   
 
 
respectively in the D1 spectrum. The max in D spectrum is a wavelength of zero 
slope and gives dA/d ƛ = 0 in the D1 spectrum. 
The second derivative D2 spectrum is a plot of the curvature of the D spectrum 
against wavelength or a plot o f d2A/dȜ2 vs. Ȝ. The maximum negative curvature 
in the D spectrum gives two small maxima called satellite bands in the D2 
spectrum, and the maximum positive curvature in the D spectrum gives two small 
maxim a called satellite bands in the D2 spectrum. The wavelength of maximum 
slope and zero curvature in the D spectrum correspond with cross-over points in 
the D2 spectrum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: (a) The Zeroth, (b) first, (c) second derivative 
spectra of guassian band 
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These spectral transformations confer two principal advantages on derivative 
spectrophotometry. Firstly, Zero order spectrum is of narrower spectral 
bandwidth than its fundamental spectrum. A derivative spectrum therefore shows 
better resolution of overlapping bands than the fundamental spectrum and may 
permit the accurate determination of the ƛmax of the individual bands. Secondly, 
derivative spectrophotometry discriminates in favour of substances of narrow 
spectral bandwidth against broad bandwidth substances. All the amplitudes in 
the derivative spectrum are proportional to the concentration of the analyte, 
provided that Beer’s law is obeyed by the fundamental spectrum. 
 
The enhanced resolution and bandwidth discrimination increases with increasing 
derivative order. However, it is also found that the concomitant increase in 
electronic noise inherent in the generation of the higher order spectra, and the 
consequent reduction of the signal to noise ratio, place serious practical 
limitations on the higher order spectra. For quantitative purposes, second and 
fourth derivative spectra are the most frequently employed derivative orders. 
 
A first-order derivative is the rate of change of absorbance with respect to 
wavelength. A first order derivative starts and finishes at zero. It also passes 
through zero at the same wavelength as maximum of the absorbance band. 
Either sides of this point are positive and negative bands with maximum and 
minimum at the same wavelengths as the inflection points in the absorbance 
band. This bipolar function is characteristic of all odd-order derivatives. 
 
Derivative spectra may be generated by any of three techniques. The earliest 
derivative spectra were obtained by modification of the optical system. 
Spectrophotometers with dual monochromator set a small wavelength interval 
(typically 1-3 nm) apart or with the facility to oscillate the wavelength over a small 
range, are required. In either case the photodetectror generates a signal with 
amplitude proportional to the slope of the spectrum over the wavelength interval. 
Instruments of this type are expensive and are essentially restricted to the 
recording of first derivative spectra only. 
 
The second technique to generate derivative spectra is electronic differentiation 
of the spectrophotometer analog signal. Resistance Capacitance modules may                         
                                                         12 
   
be incorporatedin series between the spectrophotometer and recorder to provide                         
differentiation of the absorbance, not with respect to wavelength, but with respect 
to time, thereby producing the signal dA/dt. If the wavelength scan rate is 
constant (d/dt = Ce), the derivative with respect to wavelength is given by, 
 DA/d Ȝ = (dA/dt)/ (d/dt) = (dA/dt)(1/C) 
 
Derivative spectra obtained by RC method are highly dependent on instrumental 
parameters, in particular the scan speed and the time constant. It is essential, 
therefore, to employ a standard solution of the analyte to calibrate the measured 
value the instrumental conditions selected. 
 
The third technique is based upon microcomputer differentiation. Microcomputers 
incorporated into or interfaced with the spectrophotometer may be programmed 
to provide derivative spectra during or after the scan, to measure derivative 
amplitudes between specified wavelengths and to calculate concentrations and 
associated statistics from the measured amplitude. 
 
1.5.3 Area under curve method 
 
This method utilizes two wavelength ranges. From overlain spectra of both drugs 
the area under curve is determined at both the selected analytical wavelength 
ranges. Within the above selected wavelength ranges, the area under curve was 
determined for both drugs. 
 
In this method the concentration of both drugs is calculated by solving the 
equations 1 & 2. 
Cx = (A2 aY1 – A1 aY2) / (aY1 aX2 - aY2 aX1) ----- (1) 
 
Cy = (A1 aX2 - A2 aX1) / (aY1 aX2 - aY2 aX1) ------ (2)  
Where,  Cx = Concentrations of drug X, 
Cy = Concentrations of drug Y, 
 
A1 = Area at first wavelengthrange,  
A2 = Area at second wavelength range, 
 
aX1 and aY1 are AUC constants of X and Y respectively at first 
wavelength range, aX2 and aY2 are AUC constants of X and Y 
respectively at second wavelength range, 
 
AUC constant = Area/ concentration in gm/l.     
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1.6 INTRODUCTION TO HPLC METHODS10-12 
 
Most of the drugs in multi component dosage forms can be analyzed by HPLC 
method because of the several advantages like: 
 Speed 
 
 Greater sensitivity 
 
 Improved resolution 
 
 Reusable columns 
 
 Easy sample recovery, handling and maintenance 
 
 Instrumentation tends itself to automation and quantification 
 
 Precise and reproducible results 
 
 Calculations are d one by integrator itself. 
 
Different modes of separation in HPLC are available like, normal phase mode 
and reversed phase mode. In the normal phase mode, the stationary phase is 
polar and the mobile phase is non-polar in nature. In this technique, non-polar 
compounds travel faster and are eluted first. This is because of the lower affinity 
between the non-polar compounds and the stationary phase. Polar compounds 
are retained for longer times because of their higher affinity with the stationary 
phase. These compounds, therefore take more times to elute. Normal phase 
mode of separation is therefore, not generally used for pharmaceutical 
applications because most of the drug molecules are polar in nature and hence 
take longer time to elute. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Schematic diagram of HPLC instrument 
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Various components of HPLC are: 
 
o A solvent delivery system, including pump 
 
o Sample injection system 
 
o A chromatographic column 
 
o A detector 
 
o A strip chart recorder 
 
o Data handling device and microprocessor control. 
 
Solvent delivery system 
 
A mobile phase is pumped under pressure from one or several reservoir and 
flows through the column at a constant rate. For normal phase separation eluting 
power increases with increasing polarity of the solvent but for reversed phase 
separation, eluting power decreases with increasing polarity. 
Pumps: 
 
The pump is one of the most important components of HPLC, since its 
performance directly affects retention time, reproducibility and detector 
sensitivity. 
Three main types of pumps are used in the HPLC system. 
 
1. Displacement pump 
 
2. Reciprocating pump 
 
3. Pneumatic or constant pressure pump 
 
b) Sample injection system 
 
There are three important ways of introducing the sample into 
injection port.  
1. Loop injection 
2.Valve injection                                        
3.On column 
 
(c) Chromatographic column 
 
The column is usually made up of heavy glass or stainless steel tubing to 
withstand high pressure. The columns are usually 10-30 cm long and 4-10 
mm inside diameter containing stationary phase at particle diameter of 25 
µm or less.                                           
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Columns with an internal diameter of 5 mm give good results because of 
compromise between efficiency, sample capacity, and the amount of packing 
and solvent required. 
Column packing: 
 
The packing used in modern HPLC consist of small, rigid particles having a 
narrow particle size distribution. There are three main types of column packing in 
HPLC. 
1. Porous, polymeric beds 
  
2. Porous layer beds 
 
3. Totally Porous silica particles (dia. <10 µm) 
 
d) Detectors 
 
The function of the detector in HPLC is to monitor the mobile phase as it merges 
from the column. Detectors are usually of two types: 
1. Bulk property detectors: It compares overall changes in a physical property of 
the mobile phase with and without an eluting solute. e.g. refractive index, 
dielectric constant or density. 
 
2.Solute property detectors: It responds to a physical property of the solute which 
is not exhibited by the pure mobile phase. e.g. UV absorbance, fluorescence or 
diffusion current. Such detectors are about 1000 times more sensitive giving a 
detectable signal for a few nanogram (ng) of sample.
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LITERATURE REVIEW 
   
  
2. REVIEW OF LITERATURE 
 
 
Gangane PS  et al13 investigated and studied a HPLC method for the 
estimation of etoricoxib in both tablet and bulk formulations by using LC-10 
ATVP Shimadzu Liquid Chromatography with Hyper ODS 2 C18 size 
4.5×250 mm column as a stationary phase.Using methanol as solvent of 
flow rate of 1ml/minute. Both interday and intraday precision was found to 
be within the limits. accuracy and reproducibility were found to be 
satisfactory. 
 
Adidala RR et al14examined simultaneous estimation of paracetamol, 
aceclofenac and serratiopeptidase in tablet dosage form using C18 column 
(250mm×4.6, 5ȝ) with mobile phase consisting of acetonitrle water and 
glacial acetic acid with a flow rate of 1.0ml/minute.  Precision of drugs was 
observed to be less than 2.0 of %RSD by mean of 6 determinations.  
Linearity was observed over the concentration range 1–50 ȝg/ml (r2=0.998) 
with regression equation y = 36941x – 61362 for Paracetamol, Aceclofenac 
1–50 ȝg/mL (r2=0.997) with regression equation y = 42784x + 23799 and 
Serratiopeptidase 1-50 ȝg/mL (r2= 0.998) with regression equation y = 
1904x + 22854. LOD and LOQ of Paracetamol, aceclofenac and 
serratiopeptidase were found to be 2.27ȝg/ml, 1.1ȝg/ml, 3.62ȝ/ml and 
6.88ȝg/ml, 3.33ȝ/ml, 10.9ȝg/ml respectively. The method was validated as 
per ICH guidelines. 
 
Syed Mujdaba A et al15 developed a novel, simple, sensitive and rapid 
Chromatographic RP-HPLC method for  simultaneous estimation of 
NSAIDS (Serratiopeptidase and Diclofenac sodium) from pharmaceutical 
formulation. The present isocratic method was carried out on analytical 
column- WATERS XTERRA RP8 (4.6x150, 5 microns) with pH -3 adjusted 
mobile phase [Ortho Phosphoric acid buffer: methanol 70:30 (v/v)] at the 
flow rate 1.0 mL/min. The detection was carried out at wave length (Ȝ max) 
262 nm. The average retention time of diclofenac sodium was 3.763 min 
and Serratiopeptidase was 5.480 min. They developed method was 
validated in terms of accuracy, precision, linearity, limit of detection, limit of 
quantitation and solution stability.                                 
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Asihsh Sharma et al16 designed a simple, rapid, economical, precise and 
accurate UV spectrophotometric method for simultaneous estimation of 
Nimesulide and Serratiopeptidase in bulk drug and combined dosage form 
(Tablet Dosage form) has been developed. The method employed solving 
of simultaneous equation based on measurement of absorbance at two 
wavelengths, 276.8 nm and 389.2 nm, Ȝmax of Serratiopeptidase and 
Nimesulide respectively. The % recovery for Serratiopeptidase and 
Nimesuldie was found to be 99.3% to 101.1% and 99.76 % to 100.22%. 
 
Ashok R Parimar et al17 developed UV- visible Spectrophotometric and 
validated for Simultaneous estimation of Aceclofenac and Serratiopeptidase 
in tablet dosage form using double beam UV Spectrophotometer of thermo 
Electron Corporation (HeȜlos α) with (Ethanol + Water) as a solvent. 
Absorption maxima of Aceclofenac and Serratiopeptidase in Ethanol diluted 
with water was found to be 316 nm and 375 nm, respectively. The methods 
allow rapid analysis of binary pharmaceutical formulation with accuracy, 
precision. The method was found to be simple, accurate, precise, 
economical and robust. 
 
Vaishali DR et al18analyzed a novel rapid spectrophotometric method has 
been developed for simultaneous estimation of Serratiopeptidase and 
Diclofenac sodium by absorption ration method (Q-Method). The method 
involved solving simultaneous equations based on measurement of 
absorbance at two wavelengths 255 nm and 276 nm, the isosbestic point 
and at Ȝmax of Diclofenac sodium respectively. Beer's law was obeyed in 
the concentration range 140-240 ȝg/ml and 14-24 ȝg/ml for 
Serratiopeptidase and Diclofenac sodium respectively. 
 
Vishnu P et al19 done UV spectrophotometric baseline manipulation 
methodology for simultaneous determination of drotaverine (DRT) and 
etoricoxib (ETR) in a combined tablet dosage form has been 
developed.Spectroscopy where the amplitudes at 274 and 351 nm were 
selected to determine ETR and DRT, respectively, in combined formulation 
and methanol was used as solvent. The results of analysis have been 
validated statistically .the method which were carried out by following the 
ICH guidelines. It has been concluded that a new simple and accurate UV                          
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 spectrophotometric baseline manipulation method was developed for 
simultaneous determination of drotaverine and ETR in a combined tablet 
dosage form has been developed. 
 
Krishnaveni G et al20 developed RP-HPLC validated method for rapid 
assay of celecoxib in tablet dosage form. Isocratic elution at a flow rate of 
1.5ml/min was employed on a symmetry Chromosil C18 (250x4.6mm, 5ȝm 
in particle size) at ambient temperature. The mobile phase consisted of 
Methanol: ACN: 60:40 (V/V). The UV detection wavelength was 220 nm and 
20ȝl sample was injected. The retention time for celecoxib was 3.57 min. 
The percentage RSD for precision and accuracy of the method was found to 
be less than 2%. The method was validated as per the ICH guidelines. The 
method was successfully applied for routine analysis of celecoxib in tablet 
dosage form and bulk drug. 
 
Chaple DR et al21 opted spectrophotometric method has been developed 
for simultaneous estimation of etoricoxib and paracetamol in combined 
dosage form using multicomponent mode of analysis. It involves the 
measurements of absorbance at five selected wavelengths 235 nm, 243 
nm, 264 nm, 284 nm and 295 nm using methanol and hydrochloric acid (0.2 
N) as a solvent. Linearity was observed in the range of 1-50 ȝg/mL for 
mixture. The recovery studies confirmed the accuracy of the proposed 
method. The results were validated as per ICH guidelines.  
 
Suresh kumarS et al22 analyzed RP-HPLC method was developed for the 
simultaneous estimation of Etoricoxib(ETR) and Thiocolchicoside(THC) in 
bulk and combined tablet dosage form. Chromatography was performed on 
C18 stainless steel column (InertSil ODS-3,250 mm x 4.6 mm ID, particle 
size 5ȝm), the mobile phase used was a mixture of phosphatebuffer (PH6, 
adjusted with orthophosphoric acid) and methanol (30:70 v/v). The 
wavelengthused for detection of Etoricoxib and Thiocolchicoside was 255 
nm and flow rate of 1.2ml/min. The retention times were 2.506 min. and 
4.600 min. for EtoricoxibandThiocolchicoside, respectively. Linearity was 
determined for Etoricoxib in the range of 40-80ȝg/ml and for 
Thiocolchicoside 2-6 ȝg/ml. The correlation coefficient (‘r’) values werefound 
to be >0.999. The method was validated with respect to accuracy, precision,  
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linearity and robustness as per the ICH Guidelines.                                                                  
 
Krishna Gupta R  et al23reversed-phase HPLC method has been 
developed and subsequently validated for simultaneous estimation of 
etoricoxib (ETX) and paracetamol (PCT) from their combination product. 
The proposed RP-HPLC method utilizes a Phenomenex® C18, 5ȝm, 
250mm X 4.6mm i.d. column, mobile phase consisting of acetonitrile, 
methanol and water in the proportion of 60:15:25 (v/v/v) and UV detection at 
236.0 nm using a UV detector. The described method was linear over a 
range of 8.3-41.5 ȝg mL-1 for PCT and 1-5 ȝg mL-1 for ETX with correlation 
coefficients values of 0.9999 and 0.9993, respectively.  
 
Sanjiv Kumar et al24reverse phase high performance liquid 
chromatographic method was developed for simultaneous estimation of 
etoricoxib and thiocolchicoside in combined tablet dosage form. Formulation 
containing etoricoxib and thiocolchicoside is used as analgesic. 
Chromatography was performed on a 250 mm ◊ 4.6 mm, 5-ȝm particle size, 
BDS Hypersil C-18 column with trifluoroacetic acid buffer (pH 2.6) and 
acetonitrile (75:25, v/v) as a mobile phase. The detection of the combined 
dosage form was carried out at 220 nm and a flow rate employed was 1.5 
mL/min. The retention times were 6.6 and 3.1 min for etoricoxib and 
thiocolchicoside, respectively.  
 
SachinGholveet al25 reverse Phase High Performance Liquid 
Chromatographic (RP-HPLC) method and validate as per ICH & USP 
guidelines for the quantitative estimation of Etoricoxib in pharmaceutical 
dosage forms. The separation was conducted by using mobile phase 
consisting of methanol: ammonium acetate buffer:acetonitrile in the ratio 
(70:20:10). The separation was conducted by using Zebra Eclipse XDB-C-
18 (4.6฀~150฀~5ȝm) at the flow rate of 1.0 ml/min using variable 
wavelength detector. The precision is exemplified by relative standard 
deviation of 1.15 to 1.8 %. Percentage Mean recovery was found to be in 
the range of 97to99%, during accuracy studies. The limit of detection (LOD) 
and limit of quantitiation (LOQ) was found to be 5 ng/ml and 15 ng/ml 
respectively.           
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Venkatachalam and  lalitha KG26  Developed and validated for the 
analysis of Thiocolchicoside and ketoprofen in tablet formulations.The 
method has been shown adequate separation of both ingredients from each 
other. The chromatographic separation was carried out on a reverse phase 
column-C18 (250 mm x 4.6 mm,5ȝ), with a mobile phase consisting of 0.05 
M ammonium acetate buffer (adjusted to pH 6 with glacial acetic acid), 
acetonitrile and methanol in the ratio (50:30:20,v/v) at a flow rate of 
1.2ml/min and UV detection at 310 nm. The average recovery of the method 
is 98.88% and 100.07% for thiocolchicoside and ketoprofen respectively. 
The degree of reproducibility of the results obtained as a result of small 
deliberate variations in the method parameters and by changing analytical 
operator indicating that the method is sufficiently robust and rugged. 
 
Vaishalia et al27  Reversed phase liquid chromatography method (HPLC) 
method was developed for the quantitative estimation of celecoxib, a 
selective COX-2 inhibitor in capsule formulations. The drug was 
chromatographed on a reversed-phase C-18 column. Eluents were 
monitored at a wavelength of 220 nm using a mixture (600:400:1:1) of 
acetonitrile, Water, Triethylamine and Orthophosphoric acid. The retention 
time of Celecoxib was found to be 9.5 minutes. The flow rate of the mobile 
phase was 1.0 ml/min at room temperature. The percentage recovery lies in 
the range of 99.53%–99.75%. Solution concentrations were measured on a 
weight basis to avoid the use of an internal standard. 
 
Prinesh N. Patelet al28RP-HPLCmethod for simultaneous determination of 
9 NSAIDs (paracetamol, salicylic acid, ibuprofen, naproxen, aceclofenac, 
diclofenac, ketorolac, etoricoxib, and aspirin) and their commonly prescribed 
combination drugs (thiocolchicoside, moxifloxacin, clopidogrel, 
chlorpheniramine maleate, dextromethorphan, and domperidone) was 
established. The separation was performed on Kromasil C18 (250 × 4.6 
mm, 5 𝜇m) at 35 Degree celcius using 15mM phosphate buffer pH 3.25 and 
acetonitrile with gradient elution at a flow rate of 1.1 mL/min. Calibration           
curves were linear with correlation coefficients of determination (r2) >0.999. 
Limit of detection (LOD) and Limit of quantification (LOQ) ranged from 0.04 
to 0.97 𝜇g/mL and from 0.64 to 3.24 𝜇g/mL, respectively. 
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Gajera JB et al29spectroscopic method was developed for simultaneous 
estimation of Tizanidine Hydrochloride and Rofecoxib using Ratio Derivative 
Method. Ratio was taken using divisor. Divisor for 0.5-2.5ȝg/ml Tizanidine 
Hydrochloride was 6ȝg/ml of Rofecoxib and for 6-30ȝg/ml Rofecoxib was 
4ȝg/ml of Tizanidine Hydrochloride. After divisor spectra were converted to 
First derivative. Tizanidine Hydrochloride showed zero crossing point at 
253.00nm while Rofecoxib showed zero crossing point at 316.00nm. The 
absorbance was measured at 316.00nm for Tizanidine Hydrochloride and 
253.00nm for Rofecoxib and calibration curves were plotted as absorbance 
versus concentration, respectively. The limit of quantification was 
0.052ȝg/ml and 0.39ȝg/ml for Tizanidine Hydrochloride and Rofecoxib, 
respectively.  
 
Sekar Vet al30 reverse phase liquid chromatographic method has been 
developed and subsequently validated for simultaneous determination of 
Diacerein and Aceclofenac in combination. The separation was carried out 
using a mobile phase consisting of dipotassium hydrogen phosphate buffer 
of pH 4.5, Acetonitrile and methanol in the ratio of 40: 40: 20. The column 
used was Phenomenex Luna C18, 5ȝ, 250 mm × 4.6 mm id with flow rate of 
1.0 ml / min using UV detection at 265 nm. The described method was 
linear over a concentration range of 80-120 ȝg/ml and 160-240 ȝg/ml for the 
assay of Diacerein and Aceclofenac respectively. 
 
Raju Chandra et al31 developed and validated the stable isocratic reverse 
phase high performance liquid chromatography and UV-Visible method for 
regulate the quality and estimation of Etoricoxib drug content from the 
marketed pharmaceutical tablets. The reverse phase high performance 
liquid chromatography and UV-Visible method validation for Etoricoxib have 
done followed by assay methodology. The retention time (Rt) of Etoricoxib 
was 10.0 min with the flow rate of 1.0 mL/min at wave length 272 nm. The 
linearity of method was validated for Etoricoxib drug content in the range of 
5-100 ȝg/mL with correlation coefficient (r) values 0.997 and 0.998 for  
RP- HPLC and UV-Visible, respectively. This method is stable and validated 
to assay analysis. Thus, the validated method is can be successfully applied 
to routine analysis for regulate the quality. 
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Syal PK et al32probed RP-HPLC-PDA method has been developed for the 
simultaneous estimation of DrotaverineHCl (DRT) and Etoricoxib (ETR) in 
tablet formulations. The chromatographic separation was achieved on 
Waters Kromosil C18 column (250 mm x 4.6 mm, 5.0 ȝ particle size) using 
methanol: THF: acetatebuffer (51:09:40 v/v) pH adjusted to 6.0 with acetic 
acid, flow rate was 0.9ml/min and column was maintained at 55 0C. 
Quantification and linearity was achieved at 244 nm over the concentration 
range of 1.6 – 80ȝg/ml for DrotaverineHCl and 1.8 – 90ȝg/ml for Etoricoxib. 
The method was validated for specificity, linearity, accuracy, precision, 
LOD, LOQ and robustness. The proposed method was optimized and 
validated as per the ICH guidelines. 
 
Manish kumaret al33reverse phase high performance liquid 
chromatographic method was developed and validated for the determination 
of etoricoxib in bulk and tablet dosage forms. It was found that the excipient 
in the tablet dosage forms does not interfere in the quantification of active 
drug by proposed method. The HPLC separation was carried out by reverse 
phase chromatography on Shimadzu HPLC, 10-At detector with hypersil 
ODS C18 Column 250 X 4.6 mm (particle size of 5ȝ) and constant flow 
pump. Rheodyne injector with 20 ȝlloop with a mobile phase composed in 
the ratio acetonitrile: (0.05M) KH2PO4 buffer (50:50) at flow rate 1.8 ml 
/min. The detection was monitored at 283nm. 
 
Ashok R Parmar et al34developed and validated for Simultaneous 
estimation of Aceclofenac and Serratiopeptidase in tablet dosage form 
using double beam UV Spectrophotometer of thermo Electron Corporation 
(HeȜlos α) with (Ethanol + Water) as a solvent. Absorption maxima of 
Aceclofenac and Serratiopeptidase in Ethanol diluted with water was found 
to be 316 nm and 375 nm, respectively. Beer's law was obeyed in the 
concentration range 30-70 ȝg/ml for Aceclofenac and 100-300 ȝg/ml 
Serratiopeptidase. The mean recoveries obtained for Aceclofenac and 
Serratiopeptidase were 99.193 % and 99.153 % respectively. The LOD and                     
LOQ for Aceclofenac were found to be 2.334ȝg/ml and 7.074ȝg/ml and for 
Serratiopeptidase 12.50ȝg/ml and 37.88ȝg/ml respectively. 
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Aayushiet al35RP-HPLC method was developed for the estimation of 
Etoricoxib in pharmaceutical dosage forms. Method development 
incorporated the optimization of stationary phase (column), mobile phase 
composition and other chromatographic conditions. The method was carried 
out on Symmetry (Waters) RP-C18 (250 x 4.6 mm), 5 ȝm column using a 
mixture of Phosphate buffer: Acetonitrile in the ratio/ composition 30:70 v/v. 
The mobile phase was pumped at a flow rate of 1ml/min and the detection 
was carried out at 220 nm. The retention time of the drug was 9.585 min. 
Method validation produced excellent results for specificity, linearity, 
precision, intermediate precision, accuracy, limit of detection and limit of 
quantitation and robustness. The linearity was found within concentration 
range of 70 ppm to 130 ppm with correlation coefficient of 0.998145.  
 
VijayaKuchana et al36Reverse Phase -HPLC method was developed for 
the estimation of Etoricoxib in its bulk and tablet dosage forms, using 
symmetry C18 column (4.6×150mm, 5.0ȝm particle size) and a mobile 
phase of Methanol:Water in the ratio of 70:30(v/v),at a flow rate of 1.2ml/min 
with UV detection at 235nm.The Retention time (TR) of Etoricoxib is 2.293 
min. The proposed method is validated for system suitability, specificity, 
linearity, accuracy, precision, sensitivity, ruggedness and robustness as per 
ICH guidelines. 
KalpanaNekkala  et al37developed isocratic reverse phase liquid 
chromatography (RP-LC) method has been developed and subsequently 
validated for the determination of Celecoxib in Bulk and its pharmaceutical 
formulation. Separation was achieved with a Symmetry RP-18 ((Make: 
Waters Corporation; 75 mmx4.6 mm I.D; particle size 5 ȝm)) Column and 
Potassium dihydrogen phosphate monohydrate buffer (pH adjusted to 3.0 
with diluted orthophosphoric acid): methanol: acetonitrile (400:400:200) v/v 
as eluent at a flow rate of 0.8 mL/min. UV detection was performed at 
225nm. The method is simple, rapid, and selective. The described method 
of Celecoxib is linear over a range of 25 ȝg/mL to 75 ȝg/mL. The method    
precision for the determination of assay was below 1.0% RSD. 
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Pattan SRet al38 developedreverse phase high-pressure liquid 
chromatographic method has been developed for the simultaneous 
estimation of Paracetamol and Etoricoxib from pharmaceutical formulation. 
The method was carried out on an inertsil ODS, 5ȝ, C8-3 column, with a 
mobile phase consisting of methanol: acetonitrile: phosphate buffer pH 3.5 
(40:20:40 v/v) at a flow rate of 1.0 ml/min. Detection was carried out at 242. 
The retention time of Paracetamol and Etoricoxib were 3.27, 6.12 min. 
respectively. 
 
Santosh R et al39 quantitative estimation of Celecoxib using analytical 
grade methanol as solvent and acetyl chloride as the reagent for acetylation 
of Celecoxib has been developed. Acetyl derivative of Celecoxib obeys 
Beer’s law in concentration range 20-40 µg/ml at 270nm as absorption 
maximum. The recovery studies ascertained accuracy of purposed method 
and result validated according to ICH guidelines. The result of analysis has 
been validated statistically by recovery studies. This method was 
successfully carried out for the estimation of Celecoxib in capsule dosage 
form without the interference of common excipients. 
 
Revathiet al40 AssignedA new, simple and sensitive spectrphotometric 
method in Ultraviolet region has been developed for the determination of 
Celecoxib in bulk and in pharmaceutical formulations. Celecoxib, exhibits 
absorption maxima at 255 nm with apparent molar absorptivity 1.7848 X 
104 L/mol.cm in chloroform. Beer’s law was found to be obeyed in the 
concentration range of 2-10ug/mL. The method is accurate, precise and 
economical. This method is extended to pharmaceutical preparations. 
             
            
            
       
 
 
 
 
 
25 
   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM AND OBJECTIVE 
 
   
  
3. AIM AND OBJECTIVE 
 
      The aim and objective of the present study is a simultaneous        
estimation of Etoricoxib and Serratiopeptidase present in Multi component 
tablet dosage form by RP-HPLC is considered to be most suitable. 
 Combination of Etoricoxib and Serratiopeptidase is one of new 
combination approved by CDSCO (2010). Etoricoxib is officially reported 
in JP and Serratiopeptidase is scientific validation not reported in any 
Pharmacopoeia.  Etoricoxib and Serratiopeptidase    combinations are 
scientifically not reported on official records. 
  In our deep literature survey reveals that, not a single analytical method 
is reported for the determination of these drugs in combination and also 
during the research not following standard guidelines.   
 Based on the above reasons I have selected topic on “Simultaneous 
Estimation of Etoricoxib and Serratiopeptidase in RP-HPLC method”. 
 Also required above scientific validation for Etoricoxib and 
Serratiopeptidase combination as per ICH guidelines with the help of RP-
HPLC, Which will be useful for develop simple, sensitive, accurate, 
precise and economical spectroscopic as well as chromatographic 
analytical methods for the estimation of these two drugs in combination. 
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PLAN OF WORK 
 
 
 
   
 
Plan of the work 
 
 To perform the literature review  
 To develop simultaneous equation method for the estimation of Etoricoxib 
and Serratiopeptidase in tablet dosage 
 To develop and validate first order derivative method for estimation of 
Etoricoxib and serratiopeptidase 
 To develop and validate area under curve method for estimation of 
Etoricoxib and serratiopeptidase 
 To develop and validate RP-HPLC method for estimation of Etoricoxib and 
serratiopeptidase 
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METHODOLOGY 
 
 
 
 
   
4. DEVELOPMENT  OF SIMULTANEOUS EQUATIONS 
 
METHOD FOR ESTIMATION OF ETORICOXIB AND 
 
SERRATIOPEPTIDASE  
 
4.1 EXPERIMENTAL 
 
4.1.1 Apparatus 
 
 A double beam UV-visible Spectrophotometer (Shimadzu, UV-1700, 
Japan), attached to a computer software UV probe 2.0, with a spectral 
width of 2 nm, wavelength accuracy of 0.5 nm and pair of 1 cm matched 
quartz cells. 
  Analytical balance (CP224S, Sartorius, Germany) 
 
 Ultrasonic cleaner (Frontline FS 4, Mumbai, India) 
 
 Corning volumetric flasks and pipettes of borosilicate glass 
 
4.1.2 Reagents and Materials 
 
 Etoricoxib (ETO) and Serratiopeptidase (SER) were kindly supplied as a 
gift samples from Sun Pharma Ltd, Vadodara, Gujarat, India and Acme 
Pharmaceuticals Ltd, Ahmedabad, Gujarat, India, respectively. 
 The tablet dosage containing 50 mg ETO and 4 mg SER was prepared in 
the laboratory. 
 AR grade methanol (S.D. Fine Chemical Ltd., Mumbai, India.) 
 
 Whatman filter paper no. 41 (Whatman International Ltd., England) 
 
4.1.3 Preparation of Solutions 
 
4.1.3.1 Preparation of Standard Stock Solutions 
 
Accurately weighed portion of ETO (10 mg) and SER (10 mg) were 
transferred in a separate 100 ml of volumetric flasks. Methanol (50 ml) was 
added to 100 ml volumetric flask containing (10 mg) SER and sonicated for 
45 min. The solution of SER was filtered through whatman filter paper no. 41 
and volume of the both the volumetric flasks containing SER and ETO were 
adjusted up to the mark with methanol. 
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4.1.3.2 Preparation of Tablet dosage 
 
500 mg of tablet dosage was prepared by using ETO (90mg) and SER 
(10mg) and excipients like Microcrystaline cellulose, Starch, Magnesium 
stearate and Talc. 
4.1.3.3 Preparation of Sample Solution 
 
The tablet dosage containing ETO (50 mg) & SER (4 mg) was then 
transferred to 100 ml volumetric flask containing 50 ml methanol and 
sonicated for 20 min. The solution was filtered through Whatman filter paper 
No. 41 and the volume was adjusted up to the mark with methanol. From this 
solution 0.5 ml was taken in to a 10 ml volumetric flask and the volume was 
adjusted up to mark with methanol to get a final concentration of ETO (25 
µg/ml) and SER (2 µg/ml). 
 
4.1.4 Method Development 
 
4.1.4.1 Determination of Wavelength having Maximum Absorbance 
      Standard solutions of ETO (10 µg/ml) and SER (10 µg/ml) were scanned            
in the range of 200 to 400 nm for the determination of wavelength having  
maximum absorbance. The wavelength having maximum absorbance for ETO 
and SER were selected. 
 
4.1.4.2 Preparation of Calibration Curves 
 
      From standard stock solutions, aliquots of ETO (0.2, 0.6, 1.0, 1.4, 1.8, 
2.2, 2.6, 3.0 ml) and SER (0.2, 0.6, 1.0, 1.4, 1.8, 2.2, 2.6, 3.0 ml) were 
transferred in a series of 10 ml volumetric flasks. The volume was adjusted 
to the mark with methanol and mixed. 
 
The absorbances of all the solutions were measured at 255 nm and 288 nm 
against methanol as blank. The calibration curves were prepared by plotting 
graph of absorbance Vs concentration for both ETO and SER. 
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4.2 METHOD VALIDATION 
 
4.2.1 Linearity 
 
Linearity was observed in a concentration range of 2-30 µg/ml for both ETO 
and SER. The calibration curves were constructed by plotting the graph of 
absorbance Vs concentration.Range is the interval between upper and lower 
concentration of analyte for which it has been demonstrated that the 
analytical method has suitable level of precision, accuracy and linearity. The 
range for the method was observed in a concentration range of 2-30 µg/ml 
for both ETO and SER. For the evaluation of the range accurately measured 
standard working solutions of ETO (0.2, 0.6, 1.0, 1.4, 1.8, 2.2, 2.6, 3.0 ml) 
and SER (0.2, 0.6, 1.0, 1.4, 1.8, 2.2, 2.6, 3.0 ml) were pipette out into a 
separate series of 10 ml volumetric flasks. The volume was adjusted with 
methanol and absorbances of all the solutions were measured at 255.0 nm 
and 288.0 nm against methanol as blank. 
 
4.2.2 Method Precision (Repeatability) 
 
The precision of the instrument was checked by repeated scanning and 
measuring the absorbance of solutions (n = 6) of ETO and SER (10 µg/ml for 
both drugs) without changing the parameters of the Simultaneous Equations 
Method. The results are reported in terms of relative standard deviation (% 
RSD). 
 
4.2.3 Intermediate Precision (Reproducibility) 
 
The intraday and interday precision of the proposed method was evaluated 
by analyzing the corresponding responses 3 times on the same day and on 3 
different days over a period of 1 week for 3 different concentrations of 
standard solutions of ETO and SER (10, 14 and 18 ȝg /ml). The results were 
reported in terms of relative standard deviation (% RSD). 
 
 
 
4.2.4 Limit of Detection (LOD) & Limit of Quantification (LOQ) 
 
The limit of detection (LOD) and limit of quantitation (LOQ) of the method  
were calculated by using the following equations. 
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LOD = 3.3 X σ/S 
 
LOQ = 10 X σ/S 
 
Where, σ = the standard deviation of the response 
 
S = slope of the calibration curve 
 
4.2.5 Accuracy (% Recovery) 
 
The accuracy of the method was determined by calculating recoveries of 
ETO and SER by the standard addition method in two steps. Known 
amounts of standard solutions of ETO (7.5, 10, 12.5 µg/ml) and SER (6, 8, 
10 µg/ml) were added at 75%, 100% and 125% levels to prequantified 
sample solutions of ETO (10 µg/ml) and SER (8 µg/ml). 
 
      4.3 ANALYSIS OF DRUGS IN TABLET DOSAGE 
 
Tablet dosage of ETO and SER was prepared in laboratory. The absorbance 
of sample solution was measured against methanol as blank at 255 and 288 
nm for quantification of ETO and SER, respectively. The amount of ETO and 
SER present in the sample solutions were determined by solving the 
simultaneous equations. 
 
Concentration of both drugs is calculated by solving the simultaneous 
equations 1 & 2. 
Cx = (A2 aY1 – A1 aY2) / (aY1 aX2 - aY2 aX1) ----- (1) 
Cy = (A1 aX2 - A2 aX1) / (aY1 aX2 - aY2 aX1) ------ (2)  
Where, A1, A2= Absorbances of mixture at Ȝ1 & Ȝ2 
respectively, 
ax1 =Absorpitivity of first drug at Ȝ1, 
ax2 = Absorpitivity of first drug at Ȝ2, 
ay1=Absorpitivity of second drug at 
Ȝ1, ay2 = Absorpitivity of second 
drug at Ȝ2. 
 
 
 
 
 
      
31 
   
4.4 RESULTS AND DISCUSSION 
 
4.4.1 Method Development 
 
The working standard solutions of ETO and SER were prepared separately 
in methanol. They were scanned in the wavelength range of 200-400 nm. 
Maximum absorbance was obtained at 255 nm and 288 nm for ETO and 
SER, respectively.         
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These two wavelengths were employed for the determination of ETO and 
SER. Overlain spectra of both the drugs are shown in Figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Overlain UV Absorption Spectra of ETO (10 µg/ml) and SER (10 
µg/ml) in methanol 
 
4.4.2 Validation of the proposed method 
 
4.4.2.1 Linearity 
 
Calibration range was observed in the concentration range of 2-30 µg /ml for 
both ETO and SER. The calibration curves at different wavelengths are 
shown in Figure. 4.2, 4.3, 4.4, 4.5 
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Figure 4.2: Calibration Curve of ETO at 255 nm 
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Figure 4.3: Calibration Curve of ETO at 288 nm 
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Figure 4.4: Calibration Curve of SER at 288 nm 
 
 
 
 
 
 
 
 
 
 
 
A
bs
o
rb
an
ce
 
 
 
 
 
0.9 
 
0.8 
 
0.7 
 
0.6 
 
0.5 
 
0.4 
 
0.3      y = 0.026x + 0.009   
      R² = 0.9954   
0.2 
        
         
0.1          
0          
         
0 5 10 15 20 25 30 35 
 
Concentration (mcg/ml) 
 
 
 
Figure 4.5: Calibration Curve of SER at 255 nm 
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Table 4.1: Regression analysis data and summary of validation 
parameters for the proposed method 
PARAMETERS  ETO SER 
         
Wavelength (nm) 255  288 288 255 
         
Beer’s law limit (µg /ml) 2-30  2-30 2-30 2-30 
         
Regression equation y = 0.059x -   y = 0.005x – y = 0.029x + y = 0.026x - 
(y = mx + c) 0.011  0.006 0.014 0.009 
Slope (m) 0.059  0.005 0.029 0.026 
Intercept (c) -0.011  -0.006 0.014 -0.009 
         
Correlation coefficient (r2)  0.9998   0.9956 0.9957 0.9954 
LOD(a) (µg/ml) 0.36  0.43 0.26 0.24 
         
LOQ(b) (µg /ml) 1.10  1.29 0.79 0.72 
         
Sandell’s sensitivity  
0.01725 
 
0.1449 0.03299 0.03640 (µg/cm
2/0.001 absorbance  
 unit)       
Molar extinction        
co-efficient 17145.69  20413.45 11270.60 10213.52 
(l mol-1 cm-1)        
Repeatability (% RSDc , 
0.34 
 
0.54 0.17 0.20  
n = 6) 
 
       
Precision  Intraday  0.21-0.49   0.42-0.95 0.13-0.32 0.23-0.47 
(% RSD,          
n = 3) 
         
 
Interday 0.16-0.34 
 
0.40-0.72 0.12-0.24 0.11-0.33    
         
Accuracy ± S. D 
99.5 ± 0.26 99.87 ± 0.35 (% Recovery, n = 3)       
 
a
LOD = Limit of detection. 
b
LOQ = Limit of quantification. 
c
RSD = Relative 
standard deviation. 
d
S. D. is Standard deviation 
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4.4.2.2 Method Precision (Repeatability) 
 
The RSD values of ETO were found to be 0.34 and 0.54 % at 255 and 288 
nm respectively. The RSD values of SER were found to be 0.20 and 0.17 % 
at 255 and 288 nm (Table 4.2). Low values of RSD indicate that proposed 
method is repeatable. 
Table 4.2: Repeatability Data of ETO and SER by the proposed 
method 
 
Concentration ETORICOXIB SERRATIOPEPTIDASE  
(ETO: SER)       
(10:10 µg /ml) 
255 nm 288 nm 255 nm 
 
288nm 
 
   
       
1 0.5884 0.0428 0.2889 0.3195  
       
2 0.5892 0.0431 0.2877 0.3201  
       
3 0.5916 0.0432 0.2892 0.3197  
       
4 0.5922 0.0435 0.2881 0.3204  
       
5 0.5930 0.0433 0.2887 0.3210  
       
6 0.5931 0.0431 0.2881 0.3199  
       
Mean 0.5912 0.0431 0.2884 0.3201  
       
S.D. 0.0020 0.0002 0.0006 0.0005  
       
% RSD 0.34 0.54 0.20 0.17  
       
 
 
4.4.2.3 Intermediate Precision (Reproducibility) 
 
The RSD values of ETO for interday (0.21-0.49 % and 0.42-0.95 %) and 
intraday (0.16-0.34 % and 0.40-0.72 %) at 255 and 288 nm, respectively and 
the RSD values of SER for interday (0.13-0.32 % and 0.23-0.47 %) and 
intraday (0.12-0.24 % and 0.11-0.33 %) at 288 nm and 255 nm, reveal that 
the method is precise. 
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4.4.2.4 LOD and LOQ 
 
LOD and LOQ values for ETO were found to be 0.36 and 1.10 µg/ml, 0.43 
and 1.29 µg/ml at 255 and 288 nm, respectively. Where, LOD and LOQ 
values for SER were found to be 0.26 and 0.79 µg/ml, 0.24 and 0.72 µg/ml at 
288 nm and 255 nm, respectively. Low values of LOD & LOQ indicate that 
the method is sensitive. (Table 4.1) 
 
4.4.2.5 Accuracy (% Recovery) 
 
The recovery experiments were performed by the standard addition method. 
The mean recoveries were found to be 99.50 ± 0.26 and 99.87 ± 0.35 for 
ETO and SER respectively. The recoveries results indicate that the proposed 
method is accurate. Results of recovery studies are shown in Table 4.3 
 
Table 4.3: Recovery Data for the proposed method (n=3) 
 
 
 
Drug Amount present in 
mixture (µg/ml) 
Amount present 
in 
mixture (µg/ml) 
% Recovery ± 
S. D. (n = 3) 
 
ETO 
10 
10 
10 
75 
100 
125 
98.11 ± 0.11 
101.5 ± 0.36 
98.95 ± 0.31 
 
SER 
8 
8 
8 
75 
100 
125 
99.15 ± 0.60 
98.40 ± 0.39 
102.0 ± 0.06 
 
 
4.4.3 Assay 
 
The proposed validated method was successfully applied to determine ETO 
and SER in tablet dosage. Results are given in Table 4.4. No interference of 
the excipients with the absorbance of analyte of interest appeared; hence the 
proposed method is suitable for the routine analysis of ETO and SER in 
tablet dosage. 
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Table 4.4: Analysis of ETO and SER in tablet dosage by the proposed 
method (n=6) 
 
Synthetic 
 
Label claim (mg) 
 Amount found 
(mg) 
 % Label claim (mg) 
     
(n = 6)             
 
mixture 
               
  
ETO 
  
SER 
 
ETO 
 
SER 
 ET
O 
   
SER            
                 
 1 50  4 50.94 4.10 101.9  102.5 
                 
 2 50  4 51.02 4.06 102.0  101.5 
                 
 3 50  4 51.00 4.10 102.0  102.5 
                 
 4 50  4 51.08 4.04 102.2  101.0 
                 
 5 50  4 48.74 3.94 97.48  98.50 
                 
 6 50  4 51.04 4.08 102.1  102.1 
                 
 MEAN      50.64 4.05 101.3  101.4 
                 
 S.D.      0.93 0.06 1.86  1.52 
                 
 
 
 
4.5 CONCLUSION 
 
Based on the results obtained from the analysis using proposed method, it can 
be concluded that the method has linear response in the range of 2-30 ȝg/ml 
for both ETO and SER. The results of the analysis of tablet dosage by the 
proposed method are highly reproducible and reliable and are in good 
agreement with label claim of the drugs. The additive present in the tablet 
dosage did not interfere in the analysis. So the method can be used for the 
routine analysis of drugs in combination. 
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5.DEVELOPMENT AND VALIDATION OF AREA UNDER CURVE METHOD 
 
FOR   ESTIMATION   OF   ETORICOXIB    AND SERRATIOPEPTIDASE  
 
5.1EXPERIMENTAL 
 
5.1.1       Apparatus same as 4.1.1 
 
5.1.2       Reagent and Materials same as 4.1.2 
 
5.1.3       Preparation of solutions 
 
5.1.3.1    Preparation of Standard Stock Solution same as 4.1.3.1 
 
5.1.3.2    Preparation of Tablet dosage same as 4.1.3.2 
 
5.1.3.3 Preparation of Sample Solution same as 4.1.3.3 
 
5.1.4 Method Development 
 
5.1.4.1 Determination of analytical wavelength 
 
Standard solutions of ETO (10 µg/ml) and SER (10 µg/ml) were scanned in 
the range of 200 to 400 nm for the determination of wavelength range 
having maximum area under curve. ETO shows 250-260 nm and SER 
shows 285-295 nm as the wavelength range having maximum area under 
curve. 
 
5.1.4.2 Preparation of Calibration Curves 
 
From the standard stock solutions, aliquots of ETO (0.2, 0.6, 1.0, 1.4, 1.8, 
2.2, 2.6 ml) and SER (0.2, 0.6, 1.0, 1.4, 1.8, 2.2, 2.6 ml) were transferred in 
a series of 10 ml volumetric flasks. The volume was adjusted to the mark 
with methanol and mixed. 
 
The areas under curve of all the solutions were measured at 250-260 nm 
and 285-295 nm against methanol as blank. The calibration curves were 
prepred by plotting the graph of area under curve Vs concentration. 
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5.2METHOD VALIDATION 
 
5.2.1Linearity 
 
Linearity was observed in a concentration range of 2-26 µg/ml for both ETO 
and SER. The calibration curves were constructed by plotting the graph of 
area under curve Vs concentration.Range is the interval between upper and 
lower concentration of analytic for which it has been demonstrated that the 
analytical method has suitable level of precision, accuracy and linearity. The 
range for the method was observed in a concentration range of 2-26 µg/ml 
for both ETO and SER. For the evaluation of the range accurately 
measured standard working solutions of ETO (0.2, 0.6, 1.0, 1.4, 1.8, 2.2, 
2.6 ml) and SER (0.2, 0.6, 1.0, 1.4, 1.8, 2.2, 2.6 ml) were pipette out into 
separate series of 10 ml volumetric flasks. The volume was adjusted with 
methanol and area under curve of all the solutions were measured at 250-
260 nm and 285-295 nm against methanol as blank. 
 
5.2.2 Method Precision (Repeatability) 
 
The precision of the instrument was checked by repeated scanning and 
measuring the absorbance of solutions (n = 6) of ETO and SER (10 µg/ml for 
both drugs) without changing the parameters. The results are reported in 
terms of relative standard deviation (% RSD). 
 
5.2.3 Intermediate Precision (Reproducibility) 
 
The intraday and interday precision of the area under curve method was 
evaluated by analyzing the corresponding responses 3 times on the same day 
and on 3 different days over a period of 1 week for 3 different concentrations 
of standard solutions of ETO and SER (10, 14, and 18 ȝg /ml). The results 
were reported in terms of relative standard deviation (% RSD). 
 
5.2.4 Limit of Detection (LOD) & Limit of Quantification (LOQ) 
 
The limit of detection (LOD) and limit of quantification (LOQ) of the method 
were calculated by using the following equations. 
 LOD = 3.3 × σ/S 
 
                  LOQ = 10 × σ/S 
Where, σ = the standard deviation of the response 
             S = slope of the calibration curve 
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5.2.5 Accuracy (% Recovery) 
 
The accuracy of the method was determined by calculating recoveries of ETO 
and SER by the standard addition method in two steps. Known amounts of 
standard solutions of ETO (7.5, 10, 12.5 µg/ml) and SER (6, 8, 10 µg/ml) were 
added at 75%, 100% and 125% levels to pre-quantified sample solutions of 
ETO (10 µg/ml) and SER (8 µg/ml). 
 
5.3 ANALYSIS OF DRUGS IN TABLET DOSAGE 
 
Tablet dosage of ETO and SER was prepared in laboratory. The area under 
curve of sample solution was measured against methanol as blank at 250-260 
and 285-295 nm for quantification of ETO and SER, respectively. The amount 
of ETO and SER present in the sample solutions were determined by solving 
following AUC equations. 
 
Cx = (A2 aY1 – A1 aY2) / (aY1 aX2 - aY2 aX1) 
 
Cy = (A1 aX2 - A2 aX1) / (aY1 aX2 - 
aY2 aX1) Where, Cx = Concentration of EPE, 
 
  Cy = Concentration of LOR,  
  A1 = Area at 250-260 nm, 
  A2 = Area at 285-295 nm, 
 
aX1 and aY1 are AUC constants of ETO and SER respectively at 250-260 nm, 
 
aXnm2.and aY2 are AUC constants of ETO and SER respectively at 285-295 
AUC constant = Area/ concentration in gm/l 
 
5.4 RESULTS AND DISCUSSION 
 
5.4.1Method Development 
 
The working standard solutions of ETO and SER were prepared separately in 
methanol. Maximum area under curve was obtained at 250-260 nm and 285-
295 nm for ETO and SER, respectively. These two wavelength ranges were 
employed for the determination of ETO and SER. Overlain spectra of both the 
drugs are shown in Figure 5.1. 
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Figure 5.1: Overlain AUC spectra of ETO (10 μg/ml) and SER (10 
μg/ml) in methanol 
 
5.4.2 Validation of the proposed method  
 
5.4.2.1 Linearity 
 
      Calibration range was observed in the concentration range of 2-26 µg /ml        
for both ETO and SER. The calibration curves at different wavelength ranges 
are shown in Figure 5.2, 5.3, 5.4, 5.5. 
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Figure 5.2: Calibration Curve of ETO at 250-260 nm 
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  Figure 5.3: Calibration Curve of ETO at 285-295 nm 
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    Figure 5.4: Calibration Curve of SER at 250-260 nm 
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Figure 5.5: Calibration Curve of SER at 285-295 nm 
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Table 5.1: Regression analysis data and summary of validation  
parameters for the proposed method 
 
PARAMETERS 
 
Wavelength (nm) 
 
Beer’s law limit 
 
(µg /ml) 
 
Regression equation 
 
(y = mx + c) 
Slope (m) 
Intercept (c) 
 
Correlation coefficient 
 
(r2) 
 
LOD (µg/ml) 
 
LOQ (µg /ml) 
 
Repeatability 
 
(% RSD, n = 6) 
 
   
Precision Interday 
(% RSD,  
   
n = 3) Intraday 
   
   
Accuracy ± S. D. 
 
(% Recovery, n = 3) 
 
ETO 
 
250-260 285-295 
 
    
2-26 2-26  
    
    
y = 0.0313x  y = 0.0025x +  
- 0.0025 0.0002  
0.0313 0.0025  
-0.0025 0.0002  
    
    
0.9998 0.9976  
   
 
 
  
0.39 0.55 
 
  
   
 
 
  
1.18 1.66 
 
  
    
    
0.51 1.80  
    
    
0.54-1.09 1.20-1.92  
    
    
0.19-0.71 0.37-1.32  
    
    
 
99.82 ± 0.41 
 
SER 
 
285-295 250-260 
 
  
2-26 2-26 
 
  
y = 0.0058x y = 0.0039x 
+ 0.0060 + 0.0126 
0.0058 0.0039 
0.0060 0.0126 
  
  
0.9977 0.9964 
 
  
0.59      0.59 
1.80      1.78 
1.26      1.85 
 
0.97-1.85 1.24-1.90 
 
 
0.55-1.36 0.87-1.37 
 
 
100.2 ± 0.93 
 
LOD = Limit of detection, LOQ = Limit of quantification, 
 RSD = Relative standard deviation, S. D. = Standard deviation 
 
5.4.2.2 Method Precision (Repeatability) 
 
The RSD values of ETO were found to be 0.51 and 1.80 % at 250-260 and 
285-295 nm respectively. The RSD values of SER were found to be 1.85 and 
1.26 % at 250-260 and 285-295 nm (Table 5.2). Low values of RSD indicate 
that proposed method is repeatable. 
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Table 5.2: Repeatability data for ETO and 
SER 
                  
 Concentration  ETO SER 
 
(ETO: SER) 
               
  
250-260 nm 
 
285-295 nm 250-260 nm 
 
285-295nm  
(10:10 µg /ml) 
   
        
                  
 1  0.3139  0.0271 0.0521  0.0681          
 2 0.3182 0.0274 0.0537 0.0677 
                  
 3  0.3172  0.0279 0.0526  0.0700          
 4  0.3145  0.0270 0.0530  0.0692          
 5  0.3165  0.0265 0.0515  0.0685          
 6 0.3161 0.0276 0.0541 0.0694 
                  
 Mean 0.3160 0.0272 0.0528 0.0688 
                  
 S.D. 0.0016 0.0005 0.00098 0.00087 
                  
 % RSD 0.51 1.80 1.84 1.26 
                  
 
 
5.4.2.3 Intermediate Precision (Reproducibility) 
 
The RSD values of ETO for interday (0.54-1.09 % and 1.2-1.92 %) and intraday 
(0.19-0.71 % and 0.37-1.32 %) at 250-260 and 285-295 nm, respectively and 
the RSD values of SER for interday (1.24-1.90 % and 0.97-1.85 %) and intraday 
(0.87-1.37 % and 0.55-1.36 %) at 250-260 nm and 285-295 nm reveal that the 
method is precise. 
5.4.2.4 LOD and LOQ 
 
LOD and LOQ values for ETO were found to be 0.39 and 1.18 µg/ml, 0.55 and 
1.66 µg/ml at 250-260 and 285-295 nm, respectively. Where, LOD and LOQ 
values for LOR were found to be 0.59 and 1.80 µg/ml, 0.59 and 1.78 µg/ml at 
285-295 nm and 250-260 nm, respectively. Low values of LOD & LOQ indicate 
that the method is sensitive (Table 5.1). 
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5.4.2.5 Accuracy (% Recovery) 
 
The recovery experiments were performed by the standard addition method. 
The mean recoveries were found to be 99.82 ± 0.41 and 100.2 ± 0.93 for ETO 
and SER respectively. The recoveries results indicate that the proposed method 
is accurate. Results of recovery studies are shown in Table 5.3. 
 
Table 5.3: Recovery data for the proposed method (n = 3) 
 
  
Drug 
 Amount taken  Amount added  % Recovery ± S. D.  
 
(µg/ml) (%) 
 
(n = 3) 
 
    
              
10 75 101.3 ± 0.51 
 
     
ETO 10 100 99.32 ± 0.28  
 10 125 98.81 ± 0.44  
              
8 75 99.18 ± 1.00 
 
     
SER 8 100 100.5 ± 1.00  
 8 125 100.9 ± 0.77  
                 
S. D. is Standard deviation and n is number of replicates 
 
5.4.3 Assay 
 
The proposed validated method was successfully applied to determine ETO and 
SER in tablet dosage. Results are given in Table 5.4. No interference of the 
excipients with the absorbance of analyte of interest appeared; hence the 
proposed method is suitable for the routine analysis of ETO and SER in tablet 
dosage. 
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Table 5.4: Analysis of ETO and SER in tablet dosage by proposed 
method (n = 6) 
           
 
Synthetic 
Label claim Amount found 
(mg) 
% Label claim (mg) 
 
(mg) 
 
(n = 6)  
mixture 
    
                      
  ETO   SER ETO  SER ETO  SER 
                       
 1 50  4 50.64 3.93 101.2  98.27 
                       
 2 50  4 49.42 3.96 98.84  99.12 
                       
 3 50  4 49.68 4.03 99.36  100.9 
                       
 4 50  4 49.93 4.10 99.87  102.6 
                       
 5 50  4 50.06 3.89 100.1  97.41 
                       
 6 50  4 50.31 4.03 100.6  100.9 
                        
 Mean     50.01 3.99 100.0  99.85 
                        
 S.D.     0.44 0.08 0.87  1.92 
                       
 
 
5.5 CONCLUSION 
 
Based on the results obtained from the analysis using proposed method, it can 
be concluded that the method has linear response in the range of 2-26 ȝg/ml 
for both ETO and SER. 
The result of the analysis of tablet dosage by the proposed method is highly 
reproducible and reliable and is in good agreement with label claim of the 
drugs. The additive present in the tablet dosage did not interfere in the 
analysis. So the method can be used for the routine analysis of drugs in 
combination.         
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6.  DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR 
 
ESTIMATION OF ETORICOXIB AND SERRATIOPEPTIDASE 
 
 
6.1EXPERIMENTAL 
 
6.1.1 Apparatus 
 
 RP-HPLC instrument equipped with a UV-Visible detector and a 
photodiode array detector, (Shimadzu, LC-2010CHT, Japan,), 
autosampler, phenomenex C18 column (250 x 4.6 mm, 5 µ particle size) 
column and LC-solution software 
  Analytical balance (Sartorius CP224S, Germany) 
 
 Digital pH meter (LI 712 pH analyzer, Elico Ltd., Ahmedabad) 
 
 Corning volumetric flasks (10, 50, 100 ml) 
 
 Ultra sonic cleaner (Frontline FS 4, Mumbai, India) 
 
6.1.2 Materials and Reagents 
 
 Etoricoxib (ETO) bulk powder was kindly gifted by Sun Pharmaceuticals 
Ltd., Vadodara, Gujarat, India and Serratiopeptidase (SER) bulk powder 
was kindly gifted by Acme Pharmaceuticals Ltd., Mehsana, Gujarat, 
India, respectively 
 
 HPLC grade methanol, acetonitrile, water (Finar Chemicals Ltd., 
Mumbai, India) 
 
 Ortho-phosphoric acid (Merck Specialties Pvt. Ltd, Worli, Mumbai) 
 
 Nylon 0.45 µm – 47 mm membrane filter (Gelman Laboratory, Mumbai, 
India) 
 
 Whatman filter paper no. 41. (Whatman International Ltd., England) 
 
6.1.3 Preparation of Solutions & Reagents 
 
6.1.3.1 Preparation of Mobile Phase 
 
Mobile phase (pH 3.0) was prepared by mixing AR grade methanol, 
acetonitrile and water in the ratio of 60: 30: 10 and the pH adjusted to 3.0 
by dilute ortho-phosphoric acid. 
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6.1.3.2 Preparation of Stock Solutions of ETO (200 µg/ml) and SER 
(100 µg/ml) 
 
An accurately weighed standard ETO powder (20mg) and SER powder (10 
mg) were weighed and transferred to 100 ml separate volumetric flasks and 
dissolved in mobile phase with sonicator. The flasks were shaken and 
volumes were made up to mark with mobile phase to give a solution 
containing 200 ȝg/ml of ETO and 100 ȝg/ml of SER. 
 
6.1.3.3 Preparation of Working Standard Solutions 
 
The working standard solutions of ETO and SER were prepared by 
accurately transferring (0.5, 1, 1.5, 2.5, 3.5 and 5 ml) aliquots of ETO and 
(0.2, 0.5, 0.8, 1, 1.5 and 2 ml) aliquots of SER to 10 ml volumetric flasks 
and were made up to mark with mobile phase. 
 
6.1.3.4 Preparation of Sample Solution 
 
ETO (50 mg) and SER (4 mg) standard drug powders were accurately 
weighed and then mixed with commonly used formulation excipients like 
starch, lactose, magnesium stearate and talc in appropriate proportion. The 
mixture was then transferred to 100 ml volumetric flask containing 80 ml 
mobile phase and sonicated for 30 min. The solution was filtered through 
Whatman filter paper No. 41 and the volume was adjusted up to the mark 
with mobile phase. The above solution (1.5 ml) was transferred to 10 ml 
volumetric flask and diluted up to mark with mobile phase to obtain final 
concentration of 75 µg/ml ETO and 6 µg/ml SER. 
 
6.1.4 Chromatographic Conditions 
 
 Stationary phase:-Phenomenex C18 (250mm x 4.6mm, i.d-5µm particle 
size) column at 40ºC temperature. 
 
 Mobile Phase:- methanol: ACN: water (60: 30: 10, v/v/v) (pH-3, adjusted 
with OPA) 
 
 Flow rate:- 1.0 ml/min 
 
 Injection volume:- 20 µL 
 
 Detection:- The elution was monitored at 255 nm using PDA detector. 
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6.1.5 Determination of Analytical Wavelength 
 
The standard solutions of ETO and SER were injected under the 
chromatographic conditions above. Detection was carried out at different 
wavelength and wavelength at which best response achieved was 
determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Overlain UV Absorption Spectra of standard solutions 
of ETO (10 µg/ml) and SER (10 µg/ml) in methanol 
 
6.2METHOD VALIDATION 
 
6.2.1 Linearity 
 
Calibration curves were constructed by plotting peak area vs. concentration 
of ETO and SER, and the regression equations were calculated. The 
calibration curves were plotted over the concentration range 10-100 µg/ml 
for ETO and 2-20 µg/ml for SER. From standard stock solutions of ETO 
(0.5, 1, 1.5, 2.5, 3.5, 5 ml) and of SER (0.2, 0.5, 0.8, 1, 1.5 and 2 ml) were 
transferred to a series of 10 ml volumetric flasks and diluted to the mark 
with mobile phase methanol: ACN: water (60: 30: 10, v/v/v) (pH-3, adjusted 
with OPA). 20 µL of each solution were injected under the operating 
chromatographic conditions described above.       
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6.2.2 Method Precision (% Repeatability) 
 
The precision of the instrument was checked by repeated injected six 
sample solutions of ETO (30µg/ml) and SER (10µg/ml) under the same 
chromatographic conditions and measurement of peak area, retention time 
and tailing factor. The low %RSD values (less than 2%) indicate that 
proposed method is repeatable. 
 
6.2.3 Intermediate Precision (Reproducibility) 
 
The intraday and interday precision of the proposed method was 
determined by analyzing the corresponding responses 3 times on the same 
day and on 3 different days over a period of 1 week for 3 different 
concentrations of standard solutions of ETO (20, 30, 50 µg/ml) and SER (5, 
10, 15 µg/ml). The result was reported in terms of relative standard 
deviation (% RSD). 
 
6.2.4 Limit of Detection and Limit of Quantification 
 
LOD and LOQ of drug were calculated using the following equations 
designated by International Conference on Harmonization (ICH) guidelines. 
 LOD = 3.3 × σ/S 
LOQ = 10 × σ/S 
 
Where, σ = the standard deviation of the response and S = slope of the 
calibration curve. 
 
6.2.5 Accuracy (% Recovery) 
 
The accuracy of the method was determined by calculating recoveries of 
ETO and SER by the standard addition method in two steps. Known 
amounts of standard solutions of ETO (7.5, 10, 12.5 µg/ml) and SER (3.2, 
4, 4.8 µg/ml) were added at 80%, 100% and 120% levels to pre-quantified 
sample solutions of ETO (10 µg/ml) and SER (4 µg/ml). The amounts of 
ETO and SER were estimated by applying obtained values to the 
regression equation of the calibration curve. The value of standard 
deviation indicates that the proposed method is accurate. 
 
6.2.6 Specificity 
 
The specificity of the method was ascertained by analyzing standard drug 
solutions and sample solutions of ETO and SER. The peak purity of ETO 
and SER were assessed for standard solutions and sample solutions of 
both the drugs. 
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6.3 ANALYSIS OF DRUGS IN TABLET DOSAGE 
 
The response of the sample solutions were measured at 255 nm under the 
chromatographic conditions mentioned above for the quantification of ETO 
and SER. The amounts of ETO and SER present in the solution were 
determined by applying values of peak area to the regression equations of 
the calibration curves. 
 
6.4RESULTS AND DISCUSSION 
 
6.4.1Method development 
 
To optimize the RP-HPLC parameters, several mobile phase compositions 
were tried. A satisfactory separation and good peak symmetry for ETO and 
SER was obtained with a mobile phase methanol: ACN: water (60: 30: 10, 
v/v/v) (pH-3, adjusted with OPA) at a flow rate of 1 ml/min to get better 
reproducibility and repeatability. Quantification was carried out at 255 nm 
based on peak area. Complete resolution of the peaks with clear baseline 
was obtained (Figue 6.2). System suitability test parameters for ETO and 
SER for the proposed method are reported in Table 6.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Chromatogram of Standard Solution of ETO (50 µg/ml) and 
SER (50 µg/ml) at 255 nm 
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Table 6.1: System Suitability Parameters 
 
Parameters 
 
Retention time (min) 
 
Tailing factor 
 
Theoretical plates 
 
ET ± RSD 
 
(n = 6) 
 
2.20 ± 0.76 
 
1.2 ± 1.62 
 
2780 ± 0.47 
 
SER ± RSD 
 
(n = 6) 
 
3.15 ± 0.48 
 
1.6 ± 1.46 
 
3033 ± 1.12 
 
Resolution 
 
3.16 ± 0.2 
 
 
 
6.4.2 Validation of the proposed method 
 
The proposed method has been validated for the simultaneous 
determination of ETO and SER in tablet dosage using following 
parameters. 
 
6.4.2.1 Linearity 
 
Linear correlation was obtained between peak area Vs concentrations of 
ETO and SER in the concentration range of 10-100 µg/ml for ETO and 2-
20 µg/ml for SER. Regression parameters are mentioned in table 7.2 and 
the calibration curves of these two drugs at 264 nm are shown in Figure 
6.3, & Figure 6.4.         
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Table 6.2: Regression analysis data and summary of validation 
parameters for the proposed method 
 
 
PARAMETERS 
 
 
Detection wavelength(nm) 
 
Beer’s law limit (µg/ml) 
 
Regression equation 
y = mx + c 
 
Slope(m) 
 
Intercept(c) 
 
Correlation coefficient (r2) 
 
Repetability (% RSD, n = 6) 
 
   
 Precision Intraday(%RSD) 
 
(%RSD) 
 
  
 Interday(%RSD) 
   
   
LOD(µg/ml) 
 
LOQ(µg/ml) 
 
Accuracy ± S. D. 
 
(% Recovery, n = 3) 
RP-HPLC method 
 
      
 ETO   SER  
      
     
 255  255  
      
     
 10-100  2-20  
      
      
 y = 66969x –15461   y = 35056x + 7922  
     
  
 
  
 
66969 35056 
 
    
     
  
 
  
 
15461 7922 
 
    
     
  
 
  
 
0.9917 0.9982 
 
    
     
  
 
  
 
0.31 0.59 
 
    
      
     
 0.10-0.39  0.55-1.02  
      
     
 0.15-0.46  0.61-1.17  
     
  
 
  
 
0.35 0.19 
 
    
     
  
 
  
 
1.06 0.58 
 
    
      
     
 99.07 ± 0.42  100.8 ± 1.05  
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Figure 6.3: Calibration Curve of ETO at 255 nm 
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Figure 6.4: Calibration Curve of SER at 255 nm 6.4.2.2  
 
Method Precision (Repeatability) 
 
The RSD values for ETO and SER were found to be 0.31 and 0.59 %, 
respectively (Table 6.2 & 6.3). The RSD values were found to be < 2 %, 
which indicates that the proposed method is repeatable. 
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Table 6.3: Precision Data for ETO and 
SER     
                                     
Concentration Retention time 
 
Peak area 
  
Tailing factor 
 
       
 
(ETO: SER) 
   
(min) 
   
              
 
(30:10 µg /ml) 
                                   
ETE 
 
SER 
 
ETO SER 
 
ETO SER 
 
             
                                    
 1  2.21  3.16  1813678 371649    1.20 1.57  
                                      
 2  2.20  3.15  1814434 375939    1.21 1.59  
                                      
 3  2.18  3.13  1817370 376450    1.21 1.61  
                                      
 4  2.22  3.17  1825456 372059    1.18 1.62  
                                      
 5  2.18  3.15  1827458 372569    1.17 1.57  
                                      
 6  2.21  3.17  1820367 375721    1.22 1.62  
                                      
 Mean  2.2  3.15  1819794 374064    1.20 1.60  
                                      
 SD  0.02  0.01  5712 2193    0.02 0.02  
                                      
 % RSD  0.76  0.48  0.31 0.59    1.62 1.46  
                                       
 
6.4.2.3 Intermediate Precision (Reproducibility) 
 
The low RSD values of interday (0.15 - 0.46 % and 0.61 – 1.17 %) and 
intraday (0.10 – 0.39 % and 0.55 - 1.02 %) for ETO and SER, respectively, 
reveal that the proposed method is precise (Table 6.2). 
6.4.2.4 LOD and LOQ 
 
LOD values for ETO and SER were found to be 0.35 µg/ml and 0.19 µg/ml, 
respectively and LOQ values for ETO and SER were found to be 1.06 
µg/ml and 0.58 µg/ml, respectively (Table 6.2). These data show that the 
proposed method is sensitive for the determination of ETO and SER. 
 
6.4.2.5 Accuracy (% Recovery) 
 
The recovery experiment was performed by the standard addition method.  
The recoveries obtained were 99.07 ± 0.42 % and 100.8 ± 1.05 % for ETO  
     and SER,          
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respectively. The low value of standard deviation indicates that the proposed 
method is accurate. Results of recovery studies are shown in Table 6.4 
 
Table 6.4: Recovery Data for the proposed method 
 
           
      Amount of  Amount of  Mean  
 Drug  Level   sample taken  standard  % Recovery ±  
      (µg/ml)  spiked (%)  RSD  
                       
ETO 
 
I 
 
80 % 
  
   10  98.79 ± 0.73  
                        
II 
 
10 100 % 98.99 ± 0.31 
 
        
                       
III 10 120 % 99.42 ± 0.22 
 
        
                        
SER 
 
I 
 
4 80 % 99.79 ± 1.46 
 
      
                      
II 
 
4 100 % 101.6 ± 1.02 
 
       
                       
III 4 120 % 101.0 ± 0.65 
 
        
                        
   6.4.2.6 Specificity 
 
The specificity of the method was ascertained by analyzing standard 
solutions and for sample ETO and SER. The peak purity of std. ETE and 
SER were 1.000 and 0.9999 respectively, and for the sample ETO and SER 
peak purity were 0.9998 and 0.9998. The above results suggest that 
proposed method is specific for the simultaneous estimation of ETO and 
SER. 
 
Table 6.5: Peak purity index of standard and sample solution of ETO and SER 
 
         
 Sr No  Preparation  Peak purity  
         
      
 
  
     
ETO SER 
 
      
       
    
 
 
 
  
 
1 
 
Standard solution 1.0000 0.9999 
 
     
       
    
 
 
 
  
 
2 
 
Sample solution 0.9998 0.9998 
 
     
        
         
         
6           
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Figure 6.5 Peak Purity index of standard solution of ETO (50 µg/ml) 
 
Purity Cur e 
   mAU 
   Peak 
Zero Line    225 
0.8    210 
    
0.7 
   195 
   
180 
    
0.6    165 
    
    150 
0.5    135 
0.4 
   120 
   
105 
    
0.3    90 
    
    75 
0.2    60 
0.1 
   45 
   
30 
    
0.0    15 
    
    0 
3.00 3.15 3.30 3.45 mi 
 
Figure 6.6 Peak Purity index of standard solution of SER (50 µg/ml)                                 
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Figure 6.7 Peak Purity index of sample solution of ETO (75 µg/ml) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 Peak Purity index of sample solution of SER (6 µg/ml) 
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6.4.3 Assay of the tablet dosage 
 
The proposed validated method was successfully applied to determine 
ETO and SER in their tablet dosage. The result obtained for ETO and SER 
was comparable with the corresponding labeled amounts (Table 7.6). The 
RP-HPLC chromatogram for ETO and SER in sample was recorded and is 
shown in Figure 6.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9: Chromatogram of sample solution of ETO (75 µg/ml) 
and SER (6 µg/ml) at 255 nm 
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Table 6.6: Analysis of tablet dosage of ETO and SER by proposed 
method (n = 6) 
                 
 
Sample 
 Label Claim  Amount Found  % Label Claim  
                              
 
No. 
 ETO  SER  ETO   SER  ETO  SER  
  
(mg) 
 
(mg) 
 
(mg) 
  
(mg) (%) (%) 
 
        
                            
1 
 
50 
 
4 
49.19 4.01 98.39 100.18 
 
         
             
                            
2 
 
50 
 
4 
49.79 3.97 99.58 99.39 
 
         
             
                            
3 
 
50 
 
4 
49.58 4.03 99.17 100.9 
 
         
             
                            
4 
 
50 
 
4 
50.14 4.06 100.3 101.6 
 
         
             
                            
5 
 
50 
 
4 
49.49 3.99 98.99 99.88 
 
         
             
                            
6 
 
50 
 
4 
50.78 4.07 1012 101.8 
 
         
             
                                  
Mean 
    
99.67 100.6 
 
     49.83  4.02    
                                  
S.D. 
    
1.12 0.96 
 
     0.56  0.04    
                                
 
6.5 CONCLUSION 
 
In this proposed method, the linearity is observed in the concentration 
range of 10-100 µg/ml and 2-20 µg/ml with co-efficient of correlation, (r2) = 
0.991 and (r2) = 0.998 for ETO and SER, respectively at 255 nm. The 
results of the analysis of tablet dosage by the proposed method are highly 
reproducible and reliable and it is in good agreement with the label claim of 
the drug. The method can be used for the routine analysis of the ETO and 
SER in combination without any interference of excipients.                        
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7. COMPARISON OF ASSAY RESULTS OF THE DEVELOPED AND 
 
VALIDATED ANALYTICAL METHODS 
 
7.1ANALYSIS OF VARIANCE TEST (ANOVA) 41-42 
 
7.1.1Definition 
 
ANOVA is the “separation of variance ascribable to one group of causes from 
the variance ascribable to another group.” 
 
7.1.2 Use of ANOVA 
 
For designs with one independent variable with more than 2 groups or levels, 
using inferential statistics to determine if there are differences between these 
groups – we use Analyses of variance (ANOVA) to analyze data. ANOVA uses 
the F-statistic or F-ratio to determine if differences between groups are 
significant. 
 
7.1.3 Techniques 
 
The analysis of variance technique can be applied as follows: 
 
 One way classification means we consider the influence of only one factor. 
 
 Two way classification means we consider the influence of two factors at 
a time. In ANOVA require to calculate following terms: 
 
a)  Correction factor C.F. = T2/N, where T is grand total. 
 
b)  Sums of squares of variations amongst the C.S.S. (column sums of 
squares) 
 
C.S.S. = C12/n1 + C22/n2+ … - 
C.F.Where,C1,C2…etc. are 
column totals. 
 n1, n2 … etc. are numbers of observations in respective columns. 
 
c) Total sums of squares (T.S.S.) 
 
T.S.S. = (sum of squares of each observation) – C.F. 
 
d) Sums of squares of variations within or error 
(E.S.S.) E.S.S. = T.S.S. – (C.S.S.) 
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     Table 7.1: ANOVA    
           
Source 
 
Degrees of 
 
Sum of 
 
Mean sum of 
 
‘F’ ratio 
 
      
  
freedom 
 
squares 
 
squares 
  
        
          
 Between the  
c - 1 
 
C.S.S. 
 
C.S.S. 
   
 
columns 
      
    
c - 1 
   
 
(C.S.S.) 
        
       Large value 
Smaller value 
 
         
 
Error 
 
Difference between T.S.S. 
and C.S.S  S.S.  
 
 
  
. 
 
N -c 
  
       
         
 Total  N - 1  T.S.S.  -  -  
          
 
 
Note: While calculating F ratio we compare mean sum of squares for 
 
(i) Rows and error. 
 
(ii) Columns and error and calculate F ratio as 
 
 
 
 
 
 
 
7.2 ANOVA FOR THE DEVELOPED AND VALIDATED METHODS FOR 
ETORICOXIB AND SERRATIOPEPTIDAS 
 
For the comparison of the four developed methods i.e. simultaneous 
equations method, first order derivative method, AUC method, RP-HPLC 
method for the simultaneous estimation of Etoricoxib and Serratiopeptidase 
in tablet dosage - use analyses of variance (ANOVA). 
In the ANOVA test we have to test null hypothesis (H0) against the alternative 
hypothesis (H1).Let H0 = There are no significant differences among the four 
methods.  
H1 = There are significant differences among the four methods.                                         
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        Table 7.2: ANOVA results ofEtoricoxib       
                        
   
Sr. No. 
 
Simultaneous 
  
  
First 
  
Area under 
  
RP-HPLC 
 
           
    equations  derivative   curve   
Method 
 
       
method 
  
method 
  
method 
   
                 
                         
 
1 
   
101.88 
  
98.97 
  
101.2 
    
98.39 
   
                
                  
                         
 
2 
   
102.04 
  
98.81 
  
98.84 
    
99.58 
   
                
                  
                         
 
3 
    
102 
  
100.35 
  
99.36 
    
99.17 
   
                 
                   
                         
 
4 
   
102.16 
  
100.8 
  
99.87 
    
100.29 
   
                
                  
                         
 
5 
   
97.48 
  
99.4 
  
100.12 
    
98.99 
   
                
                  
                         
 
6 
   
102.08 
  
99.46 
  
100.6 
    
101.56 
   
                
                  
                        
  
 
Mean 
  
101.27 
  
99.63 
  
99.99 
    
99.66 
   
                
                  
                          
   
F - value 
       2.36           
         
(< 3.10) 
         
                     
                   
      Table 7.3: ANOVA calculations for Etoricoxib     
                        
   
Source of 
  
Sum of 
  
Degree of 
 
Mean 
  
Variance 
   
             
     
squares 
  
freedom 
 
squares 
  
   
variation 
        
ratio F 
   
     
(SS) 
  
(d. f.) 
 
(MS) 
    
                   
                      
   Between the  
10.74 
   
3 
  
3.58 
        
   
methods            Fc 
   
                     
                       
                     
   Within the   
30.28 
   
20 
   = 3.58/1.51    
   
methods (error)       1.51   
= 2.36 
   
                  
                       
                       
   Total   41.02953  23   -         
                     
                          
 
 
The calculated value of F is 2.36 
 
Here F calculated = 2.36 < F tabulated = 3.10 (P = 0.05). 
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So, it can be concluded that there is no significant difference among the above 
four methods. Also there is no significant difference observed to developed 
method by analysis. 
 
Table 7.4: ANOVA results for Serratiopeptidase 
 
  
Sr. No.  
 Simultaneous     First   Area under  RP-HPLC  
   equations  derivative   curve   
Method 
 
      
method 
    
method 
  
method 
   
                 
                           
 1    102.5    98.48   98.27      100.18   
                  
                           
 2    101.5    100   99.12      99.39   
                  
                           
 3    102.5    101.51   100.9      100.89   
                  
                           
 4    101    102.27   102.6      101.56   
                  
                           
 5    98.5    101.51   97.41      99.88   
                  
                           
 6    102.15    103.03   100.9      101.81   
                  
                         
 
 
Mean 
  
101.36 
   
101.13 
  
99.87 
     
100.62 
  
                
                  
                           
  
F - value 
         1.08           
          
(< 3.10) 
         
                      
                  
     Table 7.5: ANOVA calculations for Serratiopeptidase  
       
  
       
  
      
  
Source of 
 
Sum of 
  
Degree of 
 
Mean 
 
Variance 
  
             
     
squares 
  
freedom 
 
squares 
    
  
variation 
         
ratio F 
  
      
(SS) 
  
(d. f.) 
 
(MS) 
      
                   
                       
  
Between the 
  
7.89 
   
3 
  
2.63 
        
                  
  
methods 
              
Fc 
  
                      
                  
= 2.63/2.42 
  
  Within the  
48.42 
  
20 
  
2.42 
     
  
methods (error)         = 1.08   
                 
                        
  Total     56.31   23   -         
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The calculated value of F is 1.08 
 
Here F calculated = 1.08 < F tabulated = 3.10 (P = 0.05). 
 
So, it can be concluded that there is no significant difference among the 
above four methods 
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SUMMARY AND CONCLUSION 
   
 
 
 
8. SUMMARY 
 
SUMMARY OF ALL METHODS 
 
 Spectroscopic methods like Simultaneous equations method, First order 
derivative method and Area under curve method were developed for the 
simultaneous estimation of Etoricoxib and Serratiopeptidase in tablet 
dosage. 
 The developed spectroscopic methods were validated for linearity, 
accuracy, method precision, intra-day and inter-day precision, limit of 
detection and limit of quantification. 
  RP-HPLC method was developed for the simultaneous estimation of 
Etoricoxib and Serratiopeptidase in tablet dosage. 
 The developed RP-HPLC method was validated for linearity, accuracy, 
method precision, intra-day and inter-day precision, limit of detection, limit 
of quantification. 
 All the validated analytical methods were compared by applying some 
statistical treatment like ANOVA. 
 All the developed and validated methods can be successfully applied to 
determine the drugs in the tablet dosage. 
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Table 8.1: Summary of validation parameters for Simultaneous equations 
method and First order derivative method 
 Parameters  Simultaneous equations method First order derivative method  
             
 Wavelength  ETO 
255 
 ETO SER  SER ETO  SER  
 (nm) 288 288 255 264  225.2  
 Range  
2-30 2-30 2-30 2-30 2 - 30 
 
2 - 14 
 
 (µg/ml)   
           
 Correlation        
0.9984 
 
0.9956 
 
 Coefficient 0.9998 0.9956 0.9957 0.9954   
 
(r2) 
           
 % Recovery  
99.5 ± 0.26 99.87 ± 0.35 98.87 ± 0.36 
 
100.4 ± 0.69 
 
 (n = 3)   
           
 Repeatability            
 (% RSD, 0.34  0.54 0.17  0.20 1.12  1.29  
 n = 6)            
 Interday       
0.29 – 1.15 
 
0.97 – 1.33 
 
 (% RSD, 0.21- 
0.49 
 0.42- 
0.95 
0.13- 
0.32 
 
0.23-0.47 
  
 
n = 3)       
        
             
 Intraday 
0.16- 
0.34 
 
0.40- 
0.72 
0.12- 
0.24 
  
0.36 – 0.56 
 
0.68 – 1.12 
 
 (% RSD,   0.11-0.33   
 n = 3)        
           
             
 
LOD (µg/ml) 
 
    
0.36 
 
0.23 
 
 0.36  0.43 0.26  0.24   
 
LOQ (µg/ml) 
    
1.09 
 
0.71 
 
 1.10  1.29 0.79  0.72   
 Sandell’s            
 sensitivity           
 
(µg/cm2/0.001 0.01725  0.1449 0.03299  0.03640 -----  -----  
 absorbance           
 unit)            
Molar 
extinction co-
efficient (l 
mol-1 cm-1) 
 
 
17145. 
69 
20413. 
45 
11270. 
60 
10213. 
----- ----- 
52 
  
      
 Assay ± SD 101.3 ± 1.86 101.4 ± 1.52 99.63 ± 0.78 101.1 ± 1.64 
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Table 8.2: Summary of validation parameters for Area under curve 
method and RP-HPLC method 
 
Parameters 
 
 
Wavelength (nm) 
 
Range 
 
(µg/ml) 
 
Correlation 
 
Coefficient (r2) 
 
% Recovery 
 
(n = 3) 
 
Repeatability (% 
 
RSD, 
n = 6) 
 
Interday 
 
(% RSD, 
n = 3) 
 
Intraday 
 
(% RSD, 
n = 3) 
 
LOD (µg/ml) 
 
LOQ (µg/ml) 
 
Assay ± SD 
 
 Area under curve method  RP-HPLC  
              
 
ETO 
  
ETO 
 
SER 
 
SER 
 
ETO 
 
SER 
 
        
 250-260 285-295 285-295  250-260 255 255  
              
 2-26  2-26 2-26  2-26 10-100 2-20  
              
 0.9998  0.9976 0.9977  0.9964 0.9917 0.9982  
              
 99.82 ± 0.41 100.2 ± 0.93 99.07 ± 100.8 ±  
 
 
0.42 
 
1.05 
 
          
 0.51  1.80 1.26  1.85 0.31 0.59  
              
 0.54-  
1.2-1.92 
0.97-  1.24- 0.15-0.46 0.61-1.17  
 1.09  1.85  1.90      
          
              
 0.19-  0.37- 0.55-  0.87- 
0.10-0.39 0.55-1.02 
 
 0.71  1.32 1.36  1.37  
        
          
 
0.39 
 
0.55 
 
0.59 
 
0.59 
 
0.35 
 
0.19 
 
        
          
 
1.18 
 
1.66 
 
1.80 
 
1.78 
 
1.06 
 
0.58 
 
        
              
 100.0 ± 0.87 99.85 ± 1.92  99.67 ±  100.6 ±  
 
 
1.12 
 
0.96 
 
          
 
 
From the results, we can conclude that all methods are precise, linear, 
accurate and repeatable and so they can be applied for the estimation 
Etoricoxib and Serratiopeptidase in tablet dosage. The RP-HPLC method is 
more sensitive than other methods and it is also more precise, repeatable and 
specific.          
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